Market Overview
The Global Hepatocellular Carcinoma Market reached USD 977 million in 2022 and is expected to reach USD 2.4 billion by 2031 and grow with a CAGR of 12.2% during the forecast period 2024-2031. The hepatocellular carcinoma market trends show rising clinical trials, a robust pipeline, and increasing research and development. The most frequent primary liver cancer (HCC) is becoming increasingly common worldwide.
HCC continues to have a high rate of morbidity and mortality, and the cancer kills the most people worldwide. With early detection and treatment, five-year survival rates for HCC can be increased by over 60%.
Furthermore, the numerous advancements, together with rising demand for early diagnosis of carcinoma, is driving up the hepatocellular carcinoma market size. Due to the expansion of research in these fields, the market is seeing an increase in demand from North American regions.
With significant competitors like Novartis AG, F. Hoffmann-La Roche Ltd, Bristol Myers Squibb, and others actively operating in the market, the competitive struggle escalates the growth of hepatocellular carcinoma.
Market Scope
| Metrics | Details |
| CAGR | 12.2% |
| Size Available for Years | 2022-2031 |
| Forecast Period | 2024-2031 |
| Data Availability | Value (US$) |
| Segments Covered | Treatment Type, End User |
| Regions Covered | North America, Europe, Asia-Pacific, South America and Middle East & Africa |
| Fastest Growing Region | Asia-Pacific |
| Largest Region | North America |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Drug Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
For More Insights about the Market Report Free Sample
Market Dynamics
Growing Efforts for Early Diagnosis of HCC drive the growth of the Hepatocellular Carcinoma market
The rising efforts for early and fast detection of hepatocellular carcinoma in the healthcare industry are anticipated to accelerate the market's growth over the forecast period. For instance, the American Association for the Study of Liver Diseases advises HCC screening in individuals at risk, including those with cirrhosis.
The substantial correlation between HCC screening and enhanced early HCC identification, curative therapy, and decreased HCC-related mortality has been underlined by several research.
HCC has a variety of genetic, environmental, and viral causes, exhibits complex pathophysiology, and has a variable shape. Therefore, its detection is still difficult. Abdominal ultrasonography is the primary diagnostic tool used nowadays, with or without AFP biomarker screening for high-risk patients.
Translational advancements in biomarkers, next-generation sequencing (NGS), molecular imaging, artificial intelligence, and liquid biopsy are promising for earlier and more precise HCC diagnosis.
Rising Novel Product Launch and Clinical Trials Creates Lucrative Opportunities for Manufacturers
There is a growing hepatocellular carcinoma market opportunity owing to rising advancements due to increasing research and development. The rising number of clinical trials by prominent key players also drives the hepatocellular carcinoma market. Much recent study is on biomarkers advancements and utilization for treatment.
On May 29, 2023, the first biosimilar to the head and neck cancer medicine Cetuximab, Cetuxa, was made available by Alkem Laboratories. The medicine producer stated in a statement that the introduction of the drug is consistent with the company's efforts to assure affordability, accessibility, and accessibility while preserving the existence of critically ill cancer patients.
The Lack of Diagnostic Methods and Treatment Side Effects Will Hamper the Growth of the Market
The lack or absence of appropriate diagnosis methods forces patients to undergo diagnosis more frequently, increases their financial burden, and causes unwanted side effects from therapy. However, they are limiting the expansion of the global industry. Side effects of numerous chemotherapy medications can lower red and white blood cell counts, increasing the risk of infection and anemia.
The most prevalent liver cancer HCC is also the third most lethal cancer globally. The diagnosis and treatment of it have been hampered by its genetically complex and heterogeneous nature. The diagnosis of the initial disease and later recurrence has been hampered by the diagnostic efficacy of presently accessible detection techniques.
Segmentation Analysis
The Global Hepatocellular Carcinoma Market is segmented based on treatment type, End User and region.
Owing to Adoption, the Chemotherapy Segment Accounted for Approximately 36.7% of the Hepatocellular Carcinoma Market Share
The chemotherapy segment led the market for hepatocellular carcinoma, and this trend is expected to continue over the projected period 2023-2030. According to clinicaltrials.gov, 18 studies are ongoing and anticipated to be finished during the forecast period.
A few examples include a Phase 3 study sponsored by Sun Yat-sen University to assess the safety and efficacy of Sorafenib in combination with hepatic arterial infusion chemotherapy in comparison with the transarterial chemoembolization combined with Sorafenib in patients having BCLC C stage hepatocellular carcinoma.
A study on the safety and effectiveness of the treatment, Tislelizumab in combination with hyperthermic intraperitoneal chemotherapy and targeted therapy, which is utilized for hepatocellular carcinoma with high-risk, after R0 resection sponsored by the Hunan Provincial People's Hospital and is estimated to be completed by July 2025.
Geographical Share
North America Accounted for Approximately 37.2% of the Market Share, Owing to the Strong Presence of Major Players And Increasing Healthcare Infrastructure Investment.
Due to the rising need for hepatocellular carcinoma for treatment purposes in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for hepatocellular carcinoma.
The market share for hepatocellular carcinoma treatment in this region is expanding due to increased healthcare spending and public awareness, technological advancements in medicines, and an increase in biopharmaceutical establishments. The primary healthcare organizations and businesses' joint research endeavors and new product development that continuously aims to enhance available treatment options are also expected to contribute to the rising demand.
Individuals are becoming more aware of various latest products being studied for hepatocellular carcinoma leading to the market expansion in this region. The factors mentioned above further prove North America's dominance on a global scale.
Major Key Players
The major global players in the hepatocellular carcinoma market include Teva Pharmaceutical Industries Ltd., Bristol Myers Squibb, Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd, Polaris Pharmaceuticals Inc., Creative Diagnostics, Harbour BioMed and Merck & Co. Inc. among others.
Impact Analysis on Hepatocellular Carcinoma Market
Russia Ukraine Conflict Analysis
The Russia-Ukraine conflict is estimated to have a low impact on the global hepatocellular carcinoma market, owing to the low prevalence and absence of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global hepatocellular carcinoma market growth over the forecast period.
Key Developments
- On May 26, 2023, At the Annual Meeting of the American Society of Clinical Oncology (ASCO) 2023, Harbour BioMed, a biopharmaceutical business dedicated to the research, development, and commercialization of new antibody treatments, presented the findings of a phase Ib clinical study of porustobart (HBM4003) when used with toripalimab in patients having hepatocellular carcinoma (HCC).
- On September 10, 2022, In patients with formerly unattended, unresectable hepatocellular carcinoma (HCC), tislelizumab showed non-inferior overall survival (OS) over sorafenib. These findings come from the Phase III RATIONALE 301 trial. The trial achieved its main goal of being non-inferior for OS; superiority was then tested, however, it was not successful. These findings were made public with BeiGene at a late-breaking oral presentation at the ESMO Congress 2022.
- On August 3, 2022, The Phase 3 LEAP-002 trial comparing LENVIMA, an orally accessible multiple receptor tyrosine kinase inhibitor developed by Eisai, to LENVIMA monotherapy did not achieve its dual primary objectives of progression-free survival (PFS) and overall survival (OS) as the prior therapy for patients having unresectable hepatocellular carcinoma, according to a joint statement from Merck and Eisai. Patients who received KEYTRUDA along with LENVIMA experienced improvements in OS and PFS compared to those who just got LENVIMA.
Why Purchase the Report?
- To visualize the Global Hepatocellular Carcinoma Market segmentation based on treatment type, End User and region, and understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous hepatocellular carcinoma market-level data points with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as Excel consisting of key products of all the major players.
The Global Hepatocellular Carcinoma Market Report Would Provide Approximately 53 Tables, 54 Figures And 195 Pages.
Target Audience 2023
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
